荃信生物-B(02509.HK)公布，周三(23日)与Caldera Therapeutics订立一项对外授权协议，授予Caldera Therapeutics开发以及商业化QX030N的全球独家许可。
公告披露，Caldera Therapeutics获授独家、须支付特许权使用费、可转让、可再授权的权利，以在全球范围内研究、开发、注册、生产及商业化QX030N。作为回报，荃信生物或其指定联属公司将有权获得一次性、不可退还及不可抵扣的预付款1,000万美元，以及获得Caldera Therapeutics约24.88%的股权。
另外，在达成特定临床开发、监管及商业里程碑的前提下，荃信生物亦可获得最高5.45亿美元的额外付款。在QX030N首次商业销售后的一段特定时间内，荃信生物亦将有权从CalderaTherapeutics的销售净额中收取分级特许权使用费。
就授权协议而言，荃信生物与Caldera Therapeutics亦于授同日订立股份收购协议，荃信生物同意收购Caldera Therapeutics的上述股权。
据介绍，QX030N是一种处于临床前开发阶段的长效双特异性抗体，用于治疗自身免疫疾病。(js/j)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.